JP2016519063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519063A5 JP2016519063A5 JP2016502078A JP2016502078A JP2016519063A5 JP 2016519063 A5 JP2016519063 A5 JP 2016519063A5 JP 2016502078 A JP2016502078 A JP 2016502078A JP 2016502078 A JP2016502078 A JP 2016502078A JP 2016519063 A5 JP2016519063 A5 JP 2016519063A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- retinal
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785015P | 2013-03-14 | 2013-03-14 | |
| US61/785,015 | 2013-03-14 | ||
| PCT/US2014/026224 WO2014160281A2 (en) | 2013-03-14 | 2014-03-13 | Method of enhancing delivery of therapeutic compounds to the eye |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228150A Division JP2019055980A (ja) | 2013-03-14 | 2018-12-05 | 治療用化合物の眼への送達を増強する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519063A JP2016519063A (ja) | 2016-06-30 |
| JP2016519063A5 true JP2016519063A5 (enExample) | 2017-04-13 |
| JP6483083B2 JP6483083B2 (ja) | 2019-03-13 |
Family
ID=50687629
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502078A Active JP6483083B2 (ja) | 2013-03-14 | 2014-03-13 | 治療用化合物の眼への送達を増強する方法 |
| JP2018228150A Pending JP2019055980A (ja) | 2013-03-14 | 2018-12-05 | 治療用化合物の眼への送達を増強する方法 |
| JP2020188684A Pending JP2021038240A (ja) | 2013-03-14 | 2020-11-12 | 治療用化合物の眼への送達を増強する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228150A Pending JP2019055980A (ja) | 2013-03-14 | 2018-12-05 | 治療用化合物の眼への送達を増強する方法 |
| JP2020188684A Pending JP2021038240A (ja) | 2013-03-14 | 2020-11-12 | 治療用化合物の眼への送達を増強する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9730888B2 (enExample) |
| EP (1) | EP2968476B1 (enExample) |
| JP (3) | JP6483083B2 (enExample) |
| AU (2) | AU2014243925B2 (enExample) |
| CA (1) | CA2903545C (enExample) |
| WO (1) | WO2014160281A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403260D0 (en) | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
| KR102877327B1 (ko) * | 2016-08-29 | 2025-10-27 | 웨인 스테이트 유니버시티 | 개선된 광 민감성을 갖는 채널옵신 변이체에서의 돌연변이의 확인 및 이의 용도 |
| EP4653537A3 (en) * | 2016-09-02 | 2026-01-07 | Keio University | Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function |
| US11261236B2 (en) | 2017-01-06 | 2022-03-01 | Kyungpook National University Industry-Academic Cooperation Foundation | Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof |
| JP6954995B2 (ja) * | 2017-03-28 | 2021-10-27 | 森永乳業株式会社 | 非コラーゲン性糖タンパク質分解用組成物 |
| CA3141020A1 (en) * | 2019-05-17 | 2020-11-26 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy targeting retinal cells |
| EP4029521A4 (en) | 2019-09-13 | 2023-09-06 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
| US11771741B2 (en) | 2019-09-13 | 2023-10-03 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
| GB202002073D0 (en) * | 2020-02-14 | 2020-04-01 | Ucl Business Ltd | Horizontal cells |
| CA3195696A1 (en) * | 2020-09-17 | 2022-03-24 | Restore Vision Inc. | Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness |
| JP2022184212A (ja) * | 2021-05-31 | 2022-12-13 | ユニ・チャーム株式会社 | 月経血を吸収するための吸収性物品 |
| CN113355309B (zh) * | 2021-08-10 | 2021-11-05 | 迈威(上海)生物科技股份有限公司 | 重组截短型人纤维蛋白溶酶制备工艺 |
| CN117100845A (zh) * | 2022-10-24 | 2023-11-24 | 景泽生物医药(合肥)股份有限公司 | 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ511037A (en) | 1998-09-17 | 2005-02-25 | Univ Florida | Methods for treatment of degenerative retinal diseases |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| WO2007005856A1 (en) | 2005-06-30 | 2007-01-11 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment |
| US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
| WO2007131180A2 (en) * | 2006-05-04 | 2007-11-15 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| WO2009067407A2 (en) | 2007-11-19 | 2009-05-28 | Bausch & Lomb Incorporated | Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof |
| EP2451835A1 (en) * | 2009-07-10 | 2012-05-16 | ThromboGenics N.V. | Variants of plasminogen and plasmin |
| ES2534911T3 (es) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
| DK2822964T3 (en) | 2012-03-05 | 2018-12-10 | Univ Wayne State | IDENTIFICATION OF CHANNEL RHODOPSIN-2- (CHOP2) MUTATIONS AND METHODS OF USE |
-
2014
- 2014-03-13 US US14/777,420 patent/US9730888B2/en active Active
- 2014-03-13 WO PCT/US2014/026224 patent/WO2014160281A2/en not_active Ceased
- 2014-03-13 EP EP14723170.8A patent/EP2968476B1/en active Active
- 2014-03-13 JP JP2016502078A patent/JP6483083B2/ja active Active
- 2014-03-13 AU AU2014243925A patent/AU2014243925B2/en not_active Ceased
- 2014-03-13 CA CA2903545A patent/CA2903545C/en active Active
-
2017
- 2017-08-14 US US15/676,268 patent/US20180064640A1/en not_active Abandoned
-
2018
- 2018-12-05 JP JP2018228150A patent/JP2019055980A/ja active Pending
-
2019
- 2019-03-04 AU AU2019201474A patent/AU2019201474A1/en not_active Abandoned
- 2019-10-04 US US16/593,302 patent/US20200268647A1/en not_active Abandoned
-
2020
- 2020-11-12 JP JP2020188684A patent/JP2021038240A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2016534751A5 (enExample) | ||
| CN113817029B (zh) | 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用 | |
| FI2968461T3 (fi) | Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi | |
| JP2016513669A5 (enExample) | ||
| JP2013506411A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| JP2015500811A5 (enExample) | ||
| JP2019530440A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2011514314A5 (enExample) | ||
| JP2011500035A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| FI4005603T3 (fi) | Adeno-assosioituneen viruksen virioneita varianttikapsidin kera ja menetelmiä niiden käyttämiseksi | |
| JP2014510519A5 (enExample) | ||
| US20160031991A1 (en) | Targeting vaccines for veterinary use | |
| JP2014510730A5 (enExample) | ||
| RU2018119014A (ru) | АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| Bennett et al. | Hybrid flagellin as a T cell independent vaccine scaffold | |
| JP2015524413A5 (enExample) | ||
| JP2014534807A (ja) | クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ | |
| JP2017515473A5 (enExample) | ||
| JP2022541761A5 (enExample) | ||
| JP2014517690A5 (enExample) |